Natural selection shapes protein solubility to physiological requirements and recombinant applications that require higher protein concentrations are often problematic. This raises the question whether the solubility of natural protein sequences can be improved. We here show an anti-correlation between the number of aggregation prone regions (APRs) in a protein sequence and its solubility, suggesting that mutational suppression of APRs provides a simple strategy to increase protein solubility. We show that mutations at specific positions within a protein structure can act as APR suppressors without affecting protein stability. These hot spots for protein solubility are both structure and sequence dependent but can be computationally predicted. We demonstrate this by reducing the aggregation of human α-galactosidase and protective antigen of Bacillus anthracis through mutation. Our results indicate that many proteins possess hot spots allowing to adapt protein solubility independently of structure and function.
T o function proteins have to fold into their native structure while avoiding misfolding and aggregates. However, the spread in cellular abundance of proteins in a typical proteome spans about nine to ten orders of magnitude\(^1\). As protein aggregation is a concentration-dependent process the challenge posed to protein folding therefore varies enormously between low- and high-abundant proteins\(^2\). Recent evidence indicates the aggregation propensity of proteins is tuned to their cellular abundance\(^3,4\), and that cellular protein levels correlate with protein solubility\(^5\). This suggests protein solubility is on average only marginally superior to physiological expression propensity of folded proteins correlates with their solubility\(^15\).

This has important implications for the production and use of recombinant proteins in biotechnology and therapeutics. Recombinant protein applications require protein concentrations several orders of magnitude above natural abundance. As a result several potentially valuable therapeutic proteins remain beyond reach. This also raises fundamental questions on the evolutionary mechanisms allowing adapting protein solubility to changing requirements in protein abundance. Indeed, reducing the aggregation propensity of globular proteins is not a straightforward task. Globular structure requires a hydrophobic core to lock secondary structure elements into a well defined three-dimensional fold, which in turn generates aggregation prone amino acid sequences\(^7,8\). Protein structure and protein aggregation are therefore entangled properties, rendering it very difficult to remove protein aggregation without affecting protein stability and structure\(^9\). The question therefore remains how natural selection manages to co-evolve protein function and solubility without affecting the native structure of proteins and by extension, what we can learn from this to improve the properties of industrial and therapeutic recombinant proteins.

Protein aggregation is a process resulting in the accumulation of misfolded proteins into insoluble agglomerates. Although hydrophobicity is often an important driver for phase separation of misfolded proteins, structural aggregation itself is geared by more specific interactions between identical linear aggregation prone sequence regions (APRs) within the primary sequence that assemble by intermolecular β-strand interactions. The determining role of APRs in protein aggregation has been demonstrated for several amyloid-disease proteins by grafting experiments: insertion of APRs from various proteins in a non-aggregating scaffold domain results in similar aggregation propensity and morphology than the original protein from which the APR was derived\(^10-17\). On average a globular protein domain contains 2–4 APRs and ~20% of the total protein sequence of any given proteome is part of APRs\(^13,14\). It was demonstrated on a large set of *Escherichia coli* proteins that the intrinsic aggregation propensity of folded proteins correlates with their solubility\(^15\).

We show the solubility of proteins can directly be related to the number of APRs within a protein sequence and that modulating the number of APRs by mutation significantly affects protein solubility. Moreover, we perform an analysis of the relationship between protein structure and the aggregation propensity of its primary sequence over a representative set of 584 high quality crystal structures (R-factor <0.19 and resolution <1.5 Å) (ref. 16), representing all common protein folds. We find that although most residues within APRs are in a structural gridlock coupling aggregation and thermodynamic stability, specific positions in a protein structure can be mutated to lower the aggregation propensity of the primary sequence without significantly affecting protein stability. These context-dependent hotspots for solubility therefore allow to significantly improve protein solubility in a step-wise manner by point mutations that suppress individual APRs. These findings further clarify our understanding of the selective pressures relating protein structure, function and solubility. It confirms that although APRs cannot be avoided altogether in globular proteins, protein aggregation is under selective pressure. Our structural analysis demonstrates this selective pressure is not saturated but dictated by physiological requirements in protein abundance and as a result most proteins have potential for increased solubility. We illustrate these principles with two examples in which we introduced mutations in these structural hotspots thereby increasing resistance to protein aggregation without affecting structure or function: α-galactosidase, a protein currently used in replacement therapy for Fabry’s disease and the anthrax protective antigen, a key component for recombinant anthrax vaccines.

Results

**Protein abundance correlates with aggregation prone regions.** We used TANGO to predict all APRs in the *E. coli* proteome and matched these (1) to *E. coli* protein solubility (3,173 proteins) as measured by Niwa *et al.*\(^{17}\) using *in vitro* translation and (2) to cellular abundance (597 proteins) data obtained by Vogel *et al.*\(^{18}\) using mass spectrometry (Supplementary Fig. 1A). We find a good correlation (cor = −0.96) between the number of APRs and the protein solubility averaged by APR count. (Fig. 1a), consistent with the notion that the burden of additional APRs lowers the solubility of proteins. There is a large variation per category (Supplementary Fig. 1B), indicating the effect of APRs is modulated strongly by cellular and structural context. To ensure the correlation is robust, we performed a bootstrap analysis, in which we recalculated the same correlation based on 1,000 randomly selected samples, each consisting of 80% of the original data points. The bootstrapped correlations are consistently high (Supplementary Fig. 1C), supporting the robustness of the observation. Similarly, we find a good correlation (cor = −0.77) between the number of APRs in a protein sequence and cellular abundance (Fig. 1b). Again, there is quite some variation per category (Supplementary Fig. 1D), but the correlation is robust in 1,000-fold bootstrap analysis (Supplementary Fig. 1E). It was previously shown that protein solubility *in vitro* and cellular protein abundance in vivo correlate, indicating that protein solubility is tuned to their cellular abundance\(^12\). Our results therefore suggest that altering the number of APRs would have a strong effect on protein solubility and abundance. Interestingly, the correlation between intrinsic aggregation propensity and protein abundance improves when a higher TANGO cutoff is employed (cor = −0.97), although with a reduced number of datapoints in the plot (Supplementary Fig. 1F). Nevertheless, this suggests that the stronger APRs are relevant for protein abundance *in vivo*, while all regions contribute to solubility *in vitro*.

**Protein sequences possess cryptic APRs.** The existence of APRs is a consequence of globular structure and especially of the requirement of hydrophobic cores. At the same time it hampers protein folding and limits protein solubility. Not surprisingly it was found that APRs are subjected to negative selection\(^19\). The most efficient strategy to eliminate APRs consists in mutating a central hydrophobic residue in the APR to a charged residue or a Pro, as these so-called aggregation gatekeepers disfavour the β-structure adopted by hydrophobic sequences in aggregates\(^20\). However, in practice in most cases it is impossible to place charged residues at central positions within the APR without obliterating the native structure given that APRs are often part of the hydrophobic core. The next best solution to reduce aggregation is to place gatekeepers at the flanks of APRs (Fig. 1c) as these positions are relatively more solvent exposed allowing to accommodate charges with an acceptable cost to the
Figure 1 | APRs and gatekeepers in natural polypeptide sequences. (a) The scatterplot of the average experimentally determined solubility of E. coli proteins grouped by the number of APRs in their sequence displays an anti-correlation, showing that on average protein solubility decreases with increasing number of aggregation prone sequences. (b) A similar plot to A, but now for protein abundance in E. coli in vivo. Although the anti-correlation is weaker, the trend suggests that cellular abundance is also limited by the number of APRs in its sequence. (c) Schematic representation depicting the TANGO profile of a typical naturally occurring polypeptide stretch of 100 amino acids, containing two APRs (red) each flanked by an N-terminal as well as a C-terminal gatekeeper (green), as well as one suppressed APR (blue) controlled by a single suppressing gatekeeper. (d) A density plot of the TANGO scores in the set of 634 structurally diverse proteins (red), showing a strong bias towards lower scores. In the absence of gatekeeper residues, this distribution is biased towards higher scores (green). The TANGO scores of the suppressed APRs (blue) show a more even distribution including higher scoring regions. (e) Density plot showing the number of APRs occurring per 100 amino acids in 634 structurally diverse proteins (red line). The blue line shows the number of ‘suppressed APRs’, which are not detected by TANGO in the WT sequence, but show up after mutation of a single Asp, Glu, Lys, Arg or Pro residue to Ala. If mutation of such a residue reveals an APR that is undetectable in the WT sequence, we call that residue a ‘suppressing gatekeeper’. The inset shows the frequency of the amino acid type of suppressing gatekeepers. (f) Density plot of the contribution of gatekeeper residues to the overall thermodynamic stability of the native state of the protein as calculated by FoldX (red). The same plot for the suppressing gatekeepers in the same proteins (blue) is very similar.
thermodynamic stability of the protein\textsuperscript{21}. Although this does generally not allow to completely suppress protein aggregation, the almost systematic placement of charges at the flanks of APRs clearly minimizes aggregation as can be observed from the exponential distribution of APR strength in the human proteome (Fig. 1d) with the majority of APRs displaying low-to-moderate aggregation tendencies. The green curve in the plot shows that this distribution in the absence of the gatekeeper residues is shifted towards much stronger aggregation propensities.

This general situation does not imply that it is necessarily always impossible to silence an APR by placement of a central gatekeeper. In fact the selective pressure against aggregation suggests that proteins should possess a significant amount of suppressed APRs (Fig. 1c). To investigate the existence of suppressed APRs we analysed a non-redundant set (sequence identity below 30\%) of 584 proteins for which high quality crystal structures were available (R-factor better than 0.19, resolution better than 1.5 Å), which were previously selected by the WHATIF consortium\textsuperscript{22}. First, we used the TANGO software\textsuperscript{13} to identify all APRs and GKs in these proteins. However when a gatekeeper residue is most effective, it will result in a sequence that no longer scores as aggregation prone and hence, these ‘suppressing gatekeepers’ (sGKs) are not identified during the standard analysis because the APR will not be detected (it is suppressed). When such a residue is mutated to an amino acid that does not oppose aggregation, the aggregation score for the comprising region will dramatically increase, thus revealing the suppressed APR (Fig. 1c). Of course, unequivocally identifying suppressed APRs in this manner is impossible as we cannot make the difference between a previously existent APR that has been suppressed or a non-aggregating sequence that evolved one mutation away towards aggregation for other functional reasons. What this analysis can provide, however, is an idea of the number of cryptic APRs in a protein sequence and thus the number of positions within a sequence that are hotspots for susceptibility to aggregation upon mutation.

To identify sGKs we truncated all Arg, Lys, Glu, Asp and Pro residues outside of already identified APRs individually to Ala and employed TANGO to identify those residues whose truncation to Ala leads to the detection of a novel APR in the mutated sequence. The APR discovered in this way we call ‘cryptic APR’ and the residue that keeps its aggregation propensity low in the wild-type (WT) sequence ‘suppressing GK’. It should be noted that the choice for mutating to Ala is conservative mutation is a good reporter both for aggregation tendencies. The green curve in the plot shows that the distribution in the absence of the gatekeeper residues is shifted towards much stronger aggregation propensities.

sGK mutations are enriched in disease mutants. To further evaluate the importance of sGKs we analysed the frequency of loss of sGKs through mutation in the Varibench set of 19,335 disease mutations and 21,170 human non synonymous coding single-nucleotide polymorphisms. This revealed that the loss of a sGK is twice as likely in the disease set than in the polymorphism set (Fig. 2a, inset), suggesting that this type of mutation is likely to be deleterious, consistent with the notion that sGKs fulfil an important role in repressing cryptic APRs. In addition, we analysed PaxDB\textsuperscript{24}, an integrated database for the natural abundance of human proteins, comparing the abundances of proteins that contain disease-associated and neutral mutations that affect sGKs (Fig. 2a). Statistical analysis shows these distributions differ significantly (Mann–Whitney U-test P value of 5.43 × 10\textsuperscript{-11}), suggesting that mutation of a sGK in a highly abundant protein is more likely to be disease-associated than in a lowly abundant protein. This underlines the importance of this novel class of residues in polypeptide sequences.

Decreasing aggregation without affecting structure. The overall selective tendency to minimize the aggregation propensity in a proteome by flanking gatekeepers or suppressing gatekeepers does not mean that all APRs are necessarily optimized to saturation point. This idea is compatible with the observation that protein solubility is generally optimized to its physiological abundance but generally not more\textsuperscript{4,5}. The question therefore remains to what degree the aggregation of natural protein sequences is still amenable to improvement.

To investigate this, we systematically mutated every residue that is part of an APR in the same set of 634 proteins individually to Pro, Arg, Lys, Asp and Glu and recorded the predicted change in aggregation propensity (TANGO) and protein stability (ΔΔG). Figure 2b shows a density distribution of the resulting 75,720 mutations as a heat map from yellow (frequent) to red (rare), revealing as expected that for most positions in the protein sequence mutations improving the aggregation propensity of the sequence do so at a major cost for thermodynamic stability (values of 5 kcal mol\textsuperscript{-1} are unlikely to occur in an experimental setting and result from strong Van der Waals clash penalties in FoldX). However, some density can be observed in the region of the plot corresponding to a strong reduction of intrinsic aggregation at a low cost to thermodynamic stability (<1 kcal mol\textsuperscript{-1}), suggesting that additional gatekeepers at selected positions is structurally possible. As is shown in Fig. 2c, in about half the protein domains at least one such gatekeeper could be placed \textit{in silico}, suggesting there is significant potential for protein improvement at specific sites within protein structures.

To validate these principles, we experimentally investigated the effect of introducing artificial gatekeeper mutations in two example proteins: the human protein β-galactosidase and protective antigen (PA) from \textit{Bacillus anthracis}.

Rational design of aggregation-resistant β-galactosidase. Human β-galactosidase (β-Gal) is a lysosomal hydrolase. β-Gal deficiency results in Fabry disease (FD) (OMIM 301500), a metabolic X-linked inherited lysosomal storage disorder\textsuperscript{25,26}.
α-Galactosidase enzyme replacement therapy is currently used to treat FD. The structure of α-galactosidase consists of a homodimer, in which each monomer contains a (β/α) domain (Fig. 3a, central part, yellow and green parts) harbouring the active site and an antiparallel β-domain (Fig. 3a, orange and blue). The APRs of α-Gal (indicated with 1, 2 and 3 and coloured in red in Fig. 3b, upper left), cluster in the β-domain and the interface between the domains. From visual inspection of the structure, region 3 in particular is likely to be at risk of nucleating aggregation, given its edge position in the β-sheet. The results of the computational gatekeeper scan of each of the APRs of α-Gal are shown as a MASS-plot (mutant aggregation and stability spectrum), that is, a scatter plot (Fig. 3c) of the change in thermodynamic stability (ΔΔG values calculated by FoldX in kcal mol$^{-1}$) versus change in the intrinsic aggregation propensity (values calculated by TANGO, range between 0 and 100 per amino acid residue) associated to each APR. These plots allow to easily identify ideal mutations with large negative values on both axes, that is, mutations that reduce the intrinsic aggregation propensity while not decreasing the thermodynamic stability of an APR. Confirming our bioinformatics analysis above, designable positions in α-Gal exist but are sparse and context-dependent. For example, for APR1, no improving mutations could be identified, owing mainly to its complete burial inside the tightly packed domain interface. APRs 2 and 3 display one favourable mutation each (A348R and A368P, respectively), with an additional mutation in APR3 (A368R) stabilizing the region without lowering intrinsic aggregation (Fig. 3c).

In addition, to further reduce aggregation we also looked for mutations that stabilize the β-domain of the protein. Even though

---

**Figure 2 | Potential for introducing artificial gatekeepers.** (a) Comparison of the frequency of mutations that remove suppressing gatekeepers (sGKs) in pathogenic mutations and polymorphisms. The overall frequency is shown in the inset, whereas the main plot shows how the frequency of these mutations varies according to the cellular abundance of the WT proteins, showing that removal of a sGK is more likely to be neutral in proteins that occur at a low cellular concentration. (b) A systematic mutational scan of all residues of 4,730 APRs in 634 structurally diverse proteins. Each residue was mutated to Pro, Arg, Lys, Asp or Glu and its effect on intrinsic aggregation propensity and protein stability (ΔΔG) estimated using TANGO and FoldX, respectively. Heat map analysis (red to yellow gradient indicating increasing density) of the change in intrinsic aggregation propensity versus protein stability (ΔΔG) shows that the main density of mutations occurs at a high cost to thermodynamic stability and with moderate reductions of intrinsic aggregation and that only a minority of mutants significantly reduce aggregation without affecting thermodynamic stability (green box). (c) Density plot of the number of artificial gatekeepers within the green box of b that reduce significantly the aggregation propensity of an APR without affecting thermodynamic stability of the native structure (ΔΔG < 250 and ΔΔG-value < 1 kcal mol$^{-1}$).
these do not reduce APRs, the additional thermodynamic stability will minimize the detrimental effect of introducing artificial gatekeepers at other sites. An exhaustive in silico mutation scan throughout the β-domain yielded a set of mutations increasing thermodynamic stability (Table 1). The most stabilizing mutation (S405L, ΔΔG_{FoldX} = −3.34 kcal mol\(^{-1}\)) tightens the interaction of the edge β-strand (the site of APR3) with the rest of the domain. We experimentally verified the effect of all mutations, comparing them with WT α-Gal and D165V and A288D, FD mutants previously found to be particularly aggregation prone\(^2\). Mutants were transiently overexpressed in HeLa cells and α-Gal solubility was measured in lysates by western blotting of size exclusion chromatography (SEC) elution fractions (material and methods). WT protein elutes mainly as a dimer but also shows faint bands in the SEC fractions eluting at volumes corresponding to large molecular sizes (Fig. 4a) (exclusion limit of this column is 600 kDa), consistent with partial misfolding and aggregation of WT α-Gal. As expected, the disease associated mutations D165V and A288D display significant increase of these high molecular weight fractions at the expense of the dimer fraction. The
individual mutations selected to reduce aggregation show a modest decrease in the high molecular weight fractions when compared with WT α-Gal, that is most pronounced for the A348R mutant (Fig. 4a and Supplementary Fig. 2). Quantification of the solubility confirmed that while aggregating mutants (D165V and A288D) were highly insoluble (<10% of total protein), our single-point mutants reached ~80–90% solubility compared with ~70% for WT (Fig. 4b). We also determined the enzymatic activity of lysates of HEK293 cells transiently expressing α-Gal by following the conversion of the fluorogenic substrate 4-methylumbelliferyl-α-D-galactopyranoside (4-MU-α-Gal) over time. Single-point mutants showed similar enzymatic activity in comparison to WT (Fig. 4c), suggesting these mutations did not affect the active site of the enzyme and did not interfere with its enzymatic function. Overall, the effects of the single mutants are rather modest but show a decrease of aggregation and an improved solubility while leaving enzymatic activity unharmed. The fact that the observed improvements are overall modest is explained by the fact that α-Gal possesses three APRs: improving one by a single mutation leaves it susceptible to aggregation by the other regions. It is therefore expected that targeting several zones in parallel by multiple mutants should have a synergistic effect on the solubility of α-Gal.

To determine the best combinations of mutations, we generated several double (A348R/A368P and A348R/A368R) and triple mutants (A348R/A368P/S405L and A348R/A368R/S405L) consisting of the single mutations in APRs 2 and 3 and the stabilizing mutant S405L. First, we observed no significant changes in the intrinsic enzymatic activity of the mutants compared with WT (Fig. 5a) upon transient expression, showing our mutations had no major effects on the catalytic site. A similar level of soluble enzyme is reached (Fig. 5b) for WT and mutants, but there is a clear reduction of fraction of the mutants in the insoluble fraction by western blot (Fig. 5b and Supplementary Fig. 3). Moreover, this is mirrored by reduced accumulation of soluble aggregates for the mutants by SEC analysis (Fig. 5c and Supplementary Fig. 4). Together these data show the rational redesign of APRs in α-Gal is able to generate double and triple mutants that optimize protein solubility by reducing protein aggregation.

Rational design of aggregation-resistant PA. Protective antigen (PA) is an element of the protein toxin secreted by *B. anthracis*. It is a key component of recombinant Anthrax vaccines, since the immune response against this virulence factor confers protection against *B. anthracis* infection. However, recombinantly PA (rPA) stored in aqueous solution is aggregation-prone. The structure of PA reveals four domains. Domain 1 (Fig. 6a, grey) contains two calcium-binding sites and the furin cleavage site required for proteolytic activation of the molecule. Domain 2 (Fig. 6a, red) is required for membrane insertion and together with domain 3 (Fig. 6a, yellow) for heptamer formation. Domain 3 (Fig. 6a, purple) is essential for binding cell surface receptors. TANGO detects several APRs in the amino acid sequence of the protein (Fig. 6b). It was experimentally demonstrated that the solvent exposed APR (APR1, Fig. 6a, b) in domain 3 is the key determinant of rPA aggregation in vitro. Therefore, even though analysis suggests improvements are possible for all three APRs, we focused on APR1 (Fig. 6a,b, 6c).

**Figure 4 | Effect of the single mutations on α-Gal aggregation and activity.** (a) Western blot of SEC fractions of WT α-Gal, selected aggregating mutants and single mutants in transiently transfected HeLa cells. WT α-Gal and single mutants eluted in later fractions (12.5–14.5 ml) than the aggregating mutants, corresponding to the active soluble form of the protein. (b) Quantification of the solubility of α-Gal mutants in transiently transfected HeLa cells. The band densities from western blot of SEC fractions from several experiments were quantified. Fractions from 6.5–10.5 ml elution were considered as aggregated, whereas from 12.5–14.5 ml as monomeric. WT α-Gal showed approximately 75% solubility, whereas aggregating mutants were highly insoluble. Single mutants reached ~80–90% of total solubility (with the exception of the A368R mutant). Statistical significance was calculated as compared with WT α-Gal; ‘*’ *P* < 0.05 and ‘****’ *P* < 0.0001. (c) Quantification of the enzymatic activity of WT α-Gal and single mutations in transiently transfected HeLa cells. The activity of the WT and the mutants was similar, with a slight reduction in the case of the A368R mutant. Values are mean ± s.e.m.
N573IYTVLD579). The MASS plot identified position Thr576 as a suitable design hot spot, allowing for mutation to Glu, Lys and Arg. WT and three mutant proteins were recombinantly expressed in E. coli and purified (see methods). The hydrodynamic radius of the proteins was measured using dynamic light scattering (DLS) before and after heat stress (Fig. 7a), revealing a clear increase in the size of WT, consistent with aggregation. Mutants showed a mild (T576R) to strong (T576E and T576K) resistance to size increase upon heat stress suggesting lower aggregation. To corroborate this observation we analysed the T576E mutation in more detail by synthesizing the corresponding WT and mutant APR1 (NATNIYTVLDKIK and NATNIYEVLDKIK) as peptides. Analysis of secondary structure of these peptides by Fourier transform infrared spectroscopy (FTIR) (Fig. 7b) reveals the WT peptide displays an amide I band near 1,620 cm$^{-1}$, consistent with aggregation, while the mutant peptide displays a markedly different spectrum with a peak near 1,680 cm$^{-1}$ consistent with a $\beta$-turn structure. An additional in silico mutation screen using FoldX revealed the stability of the T576E mutant could be improved by 1.2 kcal mol$^{-1}$ by a compensatory mutation S559L. The corresponding double mutant protein was purified and subjected to heat stress followed by native polyacrylamide gel electrophoresis (PAGE) (Fig. 7c), revealing a clearly increased heat resistance compared with the WT and a clear improvement over the single mutation. Far and near UV circular dichroism spectroscopy (CD) (Fig. 7d) and near UV confirmed conservation of the structure between T576E/S559L and WT. Differential Scanning Calorimetry (Fig. 7e) of WT and T576E/S559L revealed only a slight increase in melting temperature Tm of the T576E/S559L mutant (47.8 $\pm$ 0.13$^\circ$C) compared with the WT (46.4 $\pm$ 0.13$^\circ$C) by 1.4$^\circ$C (t-test $P = 0.002$), but the narrower transition for the mutant is consistent with a more cooperative unfolding transition. Moreover, whereas WT shows characteristic signals of aggregation in the plot from 50$^\circ$C upwards, the T576E/S559L mutant starts aggregating only at a higher temperature, suggesting we have removed the APR responsible for aggregation during storage at room temperature. To further corroborate this observation, we performed a temperature ramped assay, in which we simultaneously measured changes in intrinsic tryptophan fluorescence (ITF) and right-angle light scattering (RALS)34,35, allowing the combined monitoring of
unfolding (Tm, Supplementary Fig. 5A) and aggregation (Tagg, Supplementary Fig. 5B) temperatures in function of a temperature gradient of 0.3°C/min. The Tm values obtained by this method are similar to those observed by DSC (46.76 ± 0.24°C and 47.23 ± 0.09°C for WT and T576E/S559L mutant, respectively). The aggregation onset temperatures differ by 2.4°C from 47.42 ± 0.01°C for WT to 49.86 ± 0.01°C for the T576E/S559L mutant, again in good agreement with the DSC data. Plotting aggregation versus degree of unfolding, it appears the aggregation onset for WT occurs at 53% of the unfolding transition, whereas for the mutant aggregation only initiates at 84% of the unfolding transition (Supplementary Fig. 5C). This is consistent with our design, in which we reduced the aggregation propensity of the strongest and most exposed APR by the T576E mutation, delaying aggregation until more advanced denaturation when the remaining APRs eventually become solvent exposed and initiate aggregation.

To further investigate the effect of the mutations on the protein structure, we solved the crystal structure of the mutant by molecular replacement (1acc (ref. 32)—Fig. 8a) to a resolution of 1.9 Å (Supplementary Table 1) leading to a model that had 0.78 Å rmsd for 675 superposed atoms (Fig. 8b), indicating our mutations were highly conservative of the structure. The mutant side chains were well defined in the electron density (Fig. 8c,d and Supplementary Fig. 6) and superposed well with the predicted side-chain conformations by FoldX (Fig. 8e,f), further validating our approach.
We verified the biological function of the protein as well as its ability to raise a protective immune response upon injection in mouse. To assay protein function, we treated Raw264.7 transformed mouse macrophage cells with T576E/S559L mutant and WT rPA in combination with B. anthracis protein lethal factor (LF) and determined the lethal dose required to kill 50% of the cells (LD50, Fig. 9a). The LD50 values for mutant and WT were identical within error: 116.3 ± 6.5 for WT and 111.6 ± 3.4 for the mutant. However, repeating the assay after increasing times of heat stress at 45 °C, WT activity decreased further than the mutant (Fig. 9b), leading to 20% residual activity of WT after 1 h at 45 °C compared with 80% for the mutant. Finally, we carried out four repeat injection of mutant rPA in mouse (days 0, 7, 10 and 18) and collected blood on day 28 to determine the response titre by ELISA (Fig. 9c). The data show that the naive animals have no anti-rPA antibodies and that after the immunization there is a clear immune response to the mutant and that the mutant antiserum recognizes WT and mutant rPA to comparable level, showing the functionality of mutant rPA as a vaccine component is also conserved. Taken together, our data indicate that mutant T576E/S559L displays a lower aggregation propensity than the WT protein, while conserving both structure and biological activity of the PA protein.

Figure 7 | Comparison of the aggregation behaviour of WT and mutant PA. (a) The hydrodynamic radius (R_h) of WT and single Gk mutant PA before (green bar) and after exposure (red bar) to thermal stress at 45 °C for 30 min. (b) Infrared amide I band of the WT (NATNIYTVLDKIK) and mutant sequence (NATNIYEVLKD) surrounding the mutation site of PA APR 1. (c) Western blot of WT, single and double mutant PA before and after exposing to thermal stress at 45 °C for 30 min. The lanes 1 and 2 of each sample represent the soluble fraction of PA under normal conditions (25 °C) and after thermal heat stress (40 °C for 30 min). (d) Far UV circular dichroism (CD) spectra of the WT and double-mutant (T576E/S559L) PA at 25 °C. (e) DSC thermogram of WT (red) and double-mutant (T576E/S559L) PA (green). (f) Static light scattering (SLS) at 473 nm measured over time for WT (red) and double-mutant (T576E/S559L) (green) at 40 °C.
Discussion

Protein aggregation is one of the main limiting factors for the use of proteins at concentrations far above those for which evolutionary selection has shaped them. Indeed, the global correlation between cellular abundance and protein solubility strongly suggests proteins are operating near their solubility limit. It follows that use of a protein at higher-than-native concentrations requires adaptation of its primary sequence, but it is not immediately apparent how much scope for improvement natural sequences harbour and how many mutations are required for notable improvements. Moreover, the fact that protein abundances are more conserved than mRNA levels could point towards a solubility deadlock for many protein sequences, potentially restricting the scope for artificial protein improvement.

On the other hand, we now understand the basic mechanisms of aggregation. Recently, several reports were made of mutationally reducing protein aggregation through either rational design or directed evolution. The most successful of these mutations involve the introduction of charged residues, which could be due to the increase of the colloidal stability by augmenting the net charge of the protein. On the other hand, these residues are also reminiscent of aggregation gatekeepers. This class of residues was discovered some time ago to flank nearly all naturally occurring APRs. These gatekeepers are usually charged amino acids and Pro, although some reports also include His and Gly. Gatekeepers kinetically control aggregation sufficiently to favour folding. Their placement at the flanks of APRs results from the fact that APRs are usually part of an element of secondary structure in the hydrophobic core of the protein, where charged or structure breaking residues cannot be accommodated. Gatekeepers are therefore enriched at the first possible polypeptide position emerging from the hydrophobic core of the protein.
Figure 9 | Comparison of the biological activity of WT and mutant PA. (a) Concentration dependence of the toxicity of PA in the presence of lethal factor to mouse macrophage Raw264.7 cells. (b) Per cent toxicity of PA in the presence of lethal factor to Raw264.7 cells after increasing times of heat stress at 45 °C to the protein sample before the assay. (c) Binding of antiserum raised against mutant PA to WT and mutant PA.

Our current analysis suggests these earlier analyses may have overlooked one of the most effective forms of aggregation gatekeepers, namely those where placement in the centre of an APR is possible, resulting in its complete suppression, thus rendering it invisible to prediction algorithms. We termed these residues suppressing gatekeepers and a survey of natural polypeptide sequences identified about 1 of these sGKs in every 100 amino acids on average. We find that sGK are more frequently mutated in disease-associated mutations than in polymorphisms, suggesting they have strong impact on protein solubility. However, protein folding and structure put many restrictions on the mutations that can be introduced in a polypeptide, and functional sites provide yet another level of complexity. We were therefore intrigued to find that at least in silico the potential for introducing additional suppressing gatekeeper residues is not exhausted in natural sequences, potentially providing a rational way to engineer more soluble protein sequences through reduced aggregation. The crux is finding the few sites where sGKs can be introduced without violating structure. We followed this up for two examples: human α-galactosidase and protective antigen from B. anthracis and found that we could reduce aggregation by exploring a very small number of mutations. In both cases, we found back charged amino acids, making it difficult to distinguish effects resulting from increased colloidal stability from those resulting from the elimination of an aggregation prone region. Given that the importance of the latter has been demonstrated in a range of experiments, the effect of the artificial introduction of suppressing gatekeepers is probably an integration of both effects in a single mutation.

Since for the two examples analysed here we managed to introduce residues reducing protein aggregation while conserving both protein structure and function one might wonder why these solutions have not been explored naturally. Of course, the concentration at which these proteins naturally occur may be below their critical concentration for aggregation or they may benefit from chaperone interactions to such an extent that aggregation is not a feature on which selection has to act. Still, it is interesting to note that of all the mutations in α-Gal and rPA that we analysed here, only one (A368P) is a naturally accessible variation, considering single codon changes of the nucleotide sequence. This would imply that even if these proteins would be under selective pressure to increase their solubility, at least this particular set of solutions is not immediately accessible.

Methods

Plasmid construction and mutagenesis. The full-length cDNA sequence encoding human α-Gal A (NM_000169) was cloned into the pcDNA4/TO/myc-His vector (Invitrogen). The insert was amplified using primers specific for the human α-Gal gene on Gene Pool cDNA template from human normal skeletal muscle (Invitrogen) with Phusion polymerase (Finnzymes). Then, the PCR product was digested with restriction enzymes Hind III and Xho I and cloned in pcDNA4/TO/myc-His vector to generate an open reading frame encoding α-Gal with a C-terminal Myc-tag. Expression vectors containing single, double and triple mutated α-Gal (D165V, A288D, A346P, A368P, A368R and S490L) were generated by site-directed mutagenesis using sequence-specific primers and PWO DNA polymerase (Roche).

The gene sequence coding for anthrax protective antigen was synthesized by GenScript and subcloned into the bacterial expression vector pET22b. This vector confers ampicillin resistance and includes the pb7 sequence for periplasmic expression. No affinity tag sequence was included. Mutants were made in house using site-directed mutagenesis and mutation was confirmed by DNA sequencing.

Cell culture and transient transfection. Human cervical cancer cell line HeLa and human osteosarcoma cell line U2OS (used for maximum 20 passages) were cultured in DMEM/F12 medium (Gibco) supplemented with 10% FCS and 1% antibiotics (penicillin/streptomycin) at 37 °C in 5% CO2. For transient transfection in six-well culture plates, 350,000 HeLa cells were plated per well in the medium without antibiotics. An amount 1 μg of plasmid DNA was transfected into HeLa cells using FuGENE HD transfection reagent (Roche) according to manufacturer’s protocol. For transient transfection in 96-well culture plates, 6,000 HeLa and U2OS cells were plated per well in the medium without antibiotics. An amount 0.1 μg of plasmid DNA was transfected into the cells using FuGENE HD transfection reagent (Roche) according to manufacturer’s protocol. Forty-eight hours after transfection, cells were removed from the incubator and examined.

SDS-PAGE and western blot. Forty-eight hours after transfection HeLa cells were lysed in RIPA buffer (1% octylphenoxypolyethoxyethanol (IGEPAL), 0.5% sodium deoxycholate and 0.1% SDS) (Pierce) supplemented with protease inhibitors (Roche) and fractionated by SDS–PAGE (NuPAGE system, Invitrogen). For Western blot the scraped cells were heated with 2% SDS buffer at 99 °C for 10 min, separated using a 10% Bis-Tris gel in MES running buffer and subsequently transferred by electroblotting (fixed current 0.4 A) on a nitrocellulose membrane (Millipore). The membrane was incubated in 5% dried non-fat milk powder dissolved in 0.2% Tris Buffer Saline-Tween (TBST) for 1 h at room temperature and subsequently incubated with primary mouse anti-myc antibody (Invitrogen) followed by incubation by secondary goat HRP-conjugated anti-mouse IgG (Promega). Proteins were visualized using chemiluminescence immunoblotting detection reagent (ECL, Millipore).

Size exclusion chromatography. For the analysis of the α-Gal aggregation state using SEC, transfected HeLa cells were lysed in RIPA buffer supplemented with protease inhibitors, centrifuged 5 min at 3,000 r.p.m. and 400 μl of the supernatant was subsequently loaded onto a Superdex S200 HR10/30 column (GE Healthcare) equilibrated in hypotonic buffer (20 mM HEPES, 10 mM KCl, 1 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 1 mM DTT and pH 7.5). Eluted fractions were concentrated by 20% trichloroacetic acid precipitation, washed with acetone and analysed by SDS–PAGE. The bands densities were quantified using the Quantity One program by 20% trichloroacetic acid precipitation, washed with acetone and analysed by SDS–PAGE. The bands densities were quantified using the Quantity One program.

Enzymatic assay. The activity of α-Gal was determined by fluorogenic substrate 4-methylumbelliferyl-α-D-galactopyranoside (5 mM 4-MU-α-Gal) as described previously. N-acetylglactosamine (D-GalNAc) was used as an inhibitor of α-Gal B activity. α-Gal B is a second α-Gal in the cells that hydrolyses the artificial
substrate but its activity in FD patients is normal or increased. In brief, HeLa cells were transfected with WT or mutant PA, transformed with 10 ng plasmid DNA (WT or mutant), plated on LB-agar plus 1 ampicillin, and incubated overnight at 37 °C. Bacterial cell pellets were recovered from 0.5 ml of cell suspension by centrifugation at 10,000g for 15 min at 4 °C. Protein was eluted with a 0–250 mM NaCl gradient, antrax protective antigen eluted at 80 mM NaCl. Anthrax Protective Antigen was immediately diluted 1:1 with ice-cold 2.5 mM K2HPO4 and then applied to a hydroxyapatite column (CHT Ceramic Hydroxyapatite, 5 ml, Bio-Rad) equilibrated with 10 column volumes 2.5 mM K2HPO4. Protein was eluted with a 2.5–500 mM K2HPO4 gradient, antrax protective antigen eluted at 5 mM K2HPO4. Both chromatographies were performed at 4 °C. Protein was concentrated by centrifugation using a molecular weight cutoff of 30,000 Da, simultaneously exchanging the buffer to 1 × PBS, 0.02% tween, 500 mM sucrose. Protein was flash frozen in liquid nitrogen and stored at −80 °C.

**Lethal factor toxicity assay.** Raw 2667 cells were seeded at 30 K cells/well in a 96-well plate and the following day a toxicity assay was performed as follows. WT PA was prepared as described above but subjected to anion exchange chromatography (HiTrap Q HP, 5 ml, GE Healthcare) which was equilibrated with three column volumes of 20 mM Hepes buffer. Protein was used diluted with a 0–250 mM NaCl gradient, antrax protective antigen eluted at 80 mM NaCl. Anthrax Protective Antigen was immediately diluted 1:1 with ice-cold 2.5 mM K2HPO4 and then applied to a hydroxyapatite column (CHT Ceramic Hydroxyapatite, 5 ml, Bio-Rad) equilibrated with 10 column volumes 2.5 mM K2HPO4. Protein was eluted with a 2.5–500 mM K2HPO4 gradient, antrax protective antigen eluted at 5 mM K2HPO4. Both chromatographies were performed at 4 °C. Protein was concentrated by centrifugation using a molecular weight cutoff of 30,000 Da, simultaneously exchanging the buffer to 1 × PBS, 0.02% tween, 500 mM sucrose. Protein was flash frozen in liquid nitrogen and stored at −80 °C.

**Protein purification.** Bacterial cell pellets were recovered from 0.5 ml of cell suspension by centrifugation at 10,000g for 15 min at 4 °C. Protein was eluted with a 0–250 mM NaCl gradient, antrax protective antigen eluted at 80 mM NaCl. Anthrax Protective Antigen was immediately diluted 1:1 with ice-cold 2.5 mM K2HPO4 and then applied to a hydroxyapatite column (CHT Ceramic Hydroxyapatite, 5 ml, Bio-Rad) equilibrated with 10 column volumes 2.5 mM K2HPO4. Protein was eluted with a 2.5–500 mM K2HPO4 gradient, antrax protective antigen eluted at 5 mM K2HPO4. Both chromatographies were performed at 4 °C. Protein was concentrated by centrifugation using a molecular weight cutoff of 30,000 Da, simultaneously exchanging the buffer to 1 × PBS, 0.02% tween, 500 mM sucrose. Protein was flash frozen in liquid nitrogen and stored at −80 °C.

**Lethal factor toxicity assay.** Raw 2667 cells were seeded at 30 K cells/well in a 96-well plate and the following day a toxicity assay was performed as follows. WT PA was prepared as described above but subjected to anion exchange chromatography (HiTrap Q HP, 5 ml, GE Healthcare) which was equilibrated with three column volumes of 20 mM Hepes buffer. Protein was used diluted with a 0–250 mM NaCl gradient, antrax protective antigen eluted at 80 mM NaCl. Anthrax Protective Antigen was immediately diluted 1:1 with ice-cold 2.5 mM K2HPO4 and then applied to a hydroxyapatite column (CHT Ceramic Hydroxyapatite, 5 ml, Bio-Rad) equilibrated with 10 column volumes 2.5 mM K2HPO4. Protein was eluted with a 2.5–500 mM K2HPO4 gradient, antrax protective antigen eluted at 5 mM K2HPO4. Both chromatographies were performed at 4 °C. Protein was concentrated by centrifugation using a molecular weight cutoff of 30,000 Da, simultaneously exchanging the buffer to 1 × PBS, 0.02% tween, 500 mM sucrose. Protein was flash frozen in liquid nitrogen and stored at −80 °C.

**Lethal factor toxicity assay.** Raw 2667 cells were seeded at 30 K cells/well in a 96-well plate and the following day a toxicity assay was performed as follows. WT PA was prepared as described above but subjected to anion exchange chromatography (HiTrap Q HP, 5 ml, GE Healthcare) which was equilibrated with three column volumes of 20 mM Hepes buffer. Protein was used diluted with a 0–250 mM NaCl gradient, antrax protective antigen eluted at 80 mM NaCl. Anthrax Protective Antigen was immediately diluted 1:1 with ice-cold 2.5 mM K2HPO4 and then applied to a hydroxyapatite column (CHT Ceramic Hydroxyapatite, 5 ml, Bio-Rad) equilibrated with 10 column volumes 2.5 mM K2HPO4. Protein was eluted with a 2.5–500 mM K2HPO4 gradient, antrax protective antigen eluted at 5 mM K2HPO4. Both chromatographies were performed at 4 °C. Protein was concentrated by centrifugation using a molecular weight cutoff of 30,000 Da, simultaneously exchanging the buffer to 1 × PBS, 0.02% tween, 500 mM sucrose. Protein was flash frozen in liquid nitrogen and stored at −80 °C.

**Protein crystallization and X-ray structure determination.** APA S559L/T576E protein solution was concentrated to 9.6 mg ml−1 and crystallization screens were set up using a Mosquito nanoliter crystallization robot (TTP Labtech). Plate-shaped crystals appeared within a couple of days and grew at 4 °C to >100 μm in size within one week under the following conditions: 20 mM MgCl2; 100 mM HEPES pH 7.5; and 22% poly(acrylic acid sodium salt) 5,100. Crystals were flash-cooled in liquid nitrogen after cryo-protection with 30% glycerol.

**Bio-informatics analysis.** TANGO13 was used to determine APRs in human proteins. This resulted in an aggregation propensity (0–100%) for each residue, whereby an aggregating segment is defined as a continuous stretch of at least five consecutive residues, each with a TANGO score higher than 5%. Each APR was assigned an average TANGO score, ranging from 0 to 100, aggregating segments are binned based on this average value. All modelling was performed using the FoldX 3b5.1 force field22 and tool suite and structural visualization was achieved using Yasara3.

**Immunization.** Polyclonal antibodies were raised in rat via a 28 days Speedy Polyclonal Antibody program at Eurogentec. WT and mutant PA were prepared as described above but subjected to anion exchange chromatography (HiTrap Q HP, 5 ml, GE Healthcare) which was equilibrated with three column volumes of 20 mM Hepes buffer. Protein was used diluted with a 0–250 mM NaCl gradient, antrax protective antigen eluted at 80 mM NaCl. Anthrax Protective Antigen was immediately diluted 1:1 with ice-cold 2.5 mM K2HPO4 and then applied to a hydroxyapatite column (CHT Ceramic Hydroxyapatite, 5 ml, Bio-Rad) equilibrated with 10 column volumes 2.5 mM K2HPO4. Protein was eluted with a 2.5–500 mM K2HPO4 gradient, antrax protective antigen eluted at 5 mM K2HPO4. Both chromatographies were performed at 4 °C. Protein was concentrated by centrifugation using a molecular weight cutoff of 30,000 Da, simultaneously exchanging the buffer to 1 × PBS, 0.02% tween, 500 mM sucrose. Protein was flash frozen in liquid nitrogen and stored at −80 °C.

**Biophysical characterization.** DLS measurements were made at room temperature with a DynaPro DLS plate reader instrument (Wyatt, Santa Barbara, CA, USA) equipped with a 830-nm laser source. Samples were placed into a flat-bottom 96-well microplate (Greiner, Frickenhausen, Germany). The autocorrelation of scattered light intensity was at a spectral resolution of 4 cm−1 by accumulating 120 data acquisitions. The spectrophotometer was continuously purged with dry air. Spectra were corrected for atmospheric interference, baseline-subtracted, and rescaled in the amide II area (1,500 to 1,600 cm−1). Circular dichroism (CD) spectra were recorded using a Jasco J-715 spectropolarimeter (Jasco, Easton, MD, USA) with a 1-cm quartz cuvette filled with the sample. The data was baseline corrected for buffer absorbance, smoothed using Savitzky-Golay algorithm, rescaled in the amide II area (1,500 to 1,600 cm−1) by accumulating 120 data acquisitions. The spectrophotometer was continuously purged with dry air. Spectra were corrected for atmospheric interference, baseline-subtracted, and rescaled in the amide II area (1,500 to 1,600 cm−1). Circular dichroism (CD) spectra were recorded using a Jasco J-715 spectropolarimeter (Jasco, Easton, MD, USA) with a 1-cm quartz cuvette filled with the sample. The data was baseline corrected for buffer absorbance, smoothed using Savitzky-Golay algorithm, rescaled in the amide II area (1,500 to 1,600 cm−1) by accumulating 120 data acquisitions. The spectrophotometer was continuously purged with dry air. Spectra were corrected for atmospheric interference, baseline-subtracted, and rescaled in the amide II area (1,500 to 1,600 cm−1).
solution of WT or mutant rPA (0.5 mg ml\(^{-1}\)) dissolved in 10 mM PBS pH 7.4 was loaded in the Micro-Cal sample cell and thermograms were recorded at a scan rate of 1 °C min\(^{-1}\) with PBS pH 7.4 as the reference cell. The thermograms were analysed and curve fitted using Micro-Cal Origin 7.0 software. The experiments were performed in triplicates using freshly prepared rPA samples.

**Agal fractionation.** HeLa cells were cultured in DMEM medium supplemented with 10% FBS, 1 mM sodium pyruvate and non-essential amino acids. For transient transfection in 6-well culture plates, 300,000 HeLa cells were plated per well and 1.5 μg of plasmid DNA was transfected into the cells using Lipofectamine 2,000 (Invitrogen) (Life Technologies). Twenty-four hours after transfection, cells were washed with cold PBS and lysed in buffer (1% octylphenoxypolyethoxyethanol (Igepal), 0.1 M Dithiothreitol (DTT) and 3 mM NaCl in Tris pH 8) supplemented with protease inhibitors (Roche). Lysates were centrifuged for 15 min at 13,400 r.p.m. at 4 °C and the supernatant was separated from the pellet. The pellets were resuspended with new buffer and dissolved in 8 μl urea for 1 h. For Western blot, samples were boiled in sample buffer (2% SDS and 1% 2-Mercaptoethanol) for 10 min, run on Any Kd gels (Biorad) and transferred to nitrocellulose membranes (Biorad). The membranes were blocked for 1 h with 5% milk powder dissolved in 0.2% TBST, incubated with primary mouse anti-myc antibody (Life technologies, (Biorad). The membranes were blocked for 1 h with 5% milk powder dissolved in 0.2% TBST, incubated with primary mouse anti-myc antibody (Life technologies, 46-0603) or primary mouse anti-GAPDH antibody (Santa Cruz, SC-32333), followed by incubation with secondary goat HRP-conjugated anti-mouse antibody (Promega). Proteins were visualized using chluminescence.

**References**

1. Mehdí, A. M., Patrick, R., Bailey, T. L. & Boden, M. Predicting the dynamics of protein abundance. *Mol. Cell. Proteomics* 13, 1330–1340 (2014).
2. Ellis, R. J. Macromolecular crowding: obvious but underappreciated. *Trends Biochem. Sci.* 26, 597–604 (2001).
3. Tartaglia, G. G. & Vendruscolo, M. Correlation between mRNA expression levels and protein aggregation propensity in subcellular localisations. *Mol. Biosyst.* 5, 1873–1876 (2009).
4. Tartaglia, G. G., Pechmann, S., Dobson, C. M. & Vendruscolo, M. A relationship between mRNA expression levels and protein solubility in *E. coli*. *J. Mol. Biol.* 388, 381–391 (2009).
5. Castillo, V., Grana-Montes, R. & Ventura, S. The aggregation properties of *Escherichia coli* proteins associated with their cellular abundance. *Biotechnol. J.* 6, 752–760 (2011).
6. Tartaglia, G. G., Pechmann, S., Dobson, C. M. & Vendruscolo, M. Life on the edge: a link between gene expression levels and aggregation rates of human proteins. *Trends Biochem. Sci.* 32, 204–206 (2007).
7. Tartaglia, G. G. & Vendruscolo, M. Proteome-level interplay between folding and aggregation propensities of proteins. *J. Mol. Biol.* 402, 919–928 (2010).
8. De Baets, G. et al. An evolutionary trade-off between protein turnover rate and protein aggregation favors a higher aggregation propensity in fast degrading proteins. *Plos Comput. Biol.* 7, e1002090 (2011).
9. Linding, R., Schymkowitz, J., Rousseau, F., Diella, F. & Serrano, L. A comparative study of the relationship between protein structure and beta-aggregation in globular and intrinsically disordered proteins. *J. Mol. Biol.* 342, 345–353 (2004).
10. Esteras-Chopo, A., Serrano, L. & de la Paz, M. L. The amyloid stretch hypothesis: recruiting proteins toward the dark side. *Proc. Natl Acad. Sci. USA* 102, 16672–16677 (2005).
11. Teng, P. K. & Eisenberg, D. Short protein segments can drive a non-fibrillizing protein into the amyloid state. *Protein Eng. Des. Sel.* 22, 531–536 (2009).
12. Ventura, S. et al. Short amino acid stretches can mediate amyloid formation in globular proteins: the Src homology 3 (SH3) case. *Proc. Natl Acad. Sci. USA* 101, 7258–7263 (2004).
13. Fernandez-Escamilla, A. M., Rousseau, F., Schymkowitz, J. & Serrano, L. Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins. *Nat. Biotechnol.* 22, 1302–1306 (2004).
14. Goldschmidt, L., Teng, P. K., Riek, R. & Eisenberg, D. Identifying the amyloide proteins capable of forming amyloid-like fibrils. *Proc. Natl Acad. Sci. USA* 107, 10487–10492 (2010).
15. Agostini, F., Vendruscolo, M. & Tartaglia, G. G. Sequence-based prediction of protein solubility. *J. Mol. Biol.* 421, 237–241 (2012).
16. Hooft, R. W., Sander, C., Scharf, M. & Friend, G. The PDBFINDER database: a side-chain planarity. *J. Appl. Crystallogr.* 29, 714–716 (1996).
17. Schymkowitz, J. et al. The FoldX web server: an online force field. *Nucleic Acids Res.* 33, W382–W388 (2005).
18. Wang, M. et al. PaxDb, a database of protein abundance averages across all three domains of life. *Mol. Cell. Proteomics* 11, 492–500 (2012).
19. Brady, R. O. et al. Enzymatic defect in Fabry’s disease. *Ceramiditrehexosidase deficiency. Nat. Engl. J. Med.* 276, 1163–1167 (1976).
20. Eng, C. M. & Desnick, R. J. Molecular basis of Fabry disease: mutations and polymorphisms in the human alpha-galactosidase A gene. *Hum. Mutat.* 3, 103–111 (1994).
21. Siekierska, A. et al. Alpha-galactosidase aggregation is a determinant of pharmacological chaperone efficacy on Fabry disease mutants. *J. Biol. Chem.* 287, 28386–28397 (2012).
22. Collier, J. R. Membrane translocation by anthrax toxin. *Mol. Aspects Med.* 30, 413–422 (2009).
23. Schymkowitz, J. W. How evolutionary pressure shaped chaperone specificity. *J. Mol. Biol.* 355, 1073–1087 (2006).
24. Rousseau, F. & Serrano, L. Schymkowitz JWH. How evolutionary pressure against protein aggregation shaped chaperone specificity. *J. Mol. Biol.* 355, 1073–1087 (2006).
25. De Baets, G., Van Durme, J., Rousseau, F. & Schymkowitz, J. A genome-wide sequence-structure analysis suggests aggregation gatekeepers constitute an evolutionary constrained functional class. *J. Mol. Biol.* 426, 2405–2412 (2014).
26. Hooft, R. W. W., Sander, C. & Friend, G. Verification of protein structures: tenacity of side-chain planarity. *J. Appl. Crystallogr.* 29, 714–716 (1996).
27. Rohou, C., Scherger, J. B., Sider, R. N. & Donaldson, M. L. Differential assay for lysosomal alpha-galactosidases in human tissues and its application to Fabry’s disease. *Clin. Chim. Acta* 112, 247–251 (1981).
28. Kabsch, W. *XDS*. *Acta Crystallogr. D.* *Biol. Crystallogr.* 66, 125–132 (2010).
29. Winn, M. D. et al. Overview of the CCP4 suite and current developments. *Acta Crystallogr. D.* *Biol. Crystallogr.* 67, 235–242 (2011).
49. Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D. Biol. Crystallogr. 66, 213–221 (2010).

50. Emsley, P., Lohkamp, R., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D. Biol. Crystallogr. 66, 486–501 (2010).

51. Kintzer, A. F., Tang, I. I., Schawel, A. K., Brown, M. J. & Krantz, B. A. Anthrax toxin protective antigen integrates poly-gamma-D-glutamate and pH signals to sense the optimal environment for channel formation. Proc. Natl Acad. Sci. USA 109, 18378–18383 (2012).

52. Chen, V. B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D. Biol. Crystallogr. 66, 12–21 (2010).

53. Krieger, E., Koraimann, G. & Vriend, G. Increasing the precision of comparative models with YASARA NOVA—a self-parameterizing force field. Proteins 47, 393–402 (2002).

54. Lieberman, R. L., D’Aquino, J. A., Ringe, D. & Petsko, G. A. Effects of pH and iminosugar pharmacological chaperones on lysosomal glycosidase structure and stability. Biochemistry 48, 4816–4827 (2009).

Acknowledgements

We thank S. Munck and N. Corhout from Light and Microscopy Network LiMoNe, VIB Center for the Biology of Disease, K.U. Leuven, Belgium for their help with the high-content analysis system using IN Cell analyser 2000. The Switch Laboratory was supported by grants from the Flanders Institute for Scientific Research Flanders (FWO), the Flanders Institute for Science and Technology (IWT) and the Federal Office for Scientific Affairs, Belgium IUAP P7. C.U. was supported by grants from PWO Vlaanderen, grants G.0939.11 and G.0762.13. We thank local contacts at beam line X06A of the Swiss Light Source for technical support. B.r.v.d.K. was supported by Boehringer Ingelheim Pharma GmbH & Co. J.S. holds an ERC CoG grant (647458).

Author contributions

F.R. and J.S. conceived the method. A.G., A.S., T.L., F.R. and J.S. designed the experiments. A.G., A.S., J.V.D., M.R., R.v.d.K., H.W. and F.D.S. performed the experiments. J.V.D., G.D.B. and J.S. performed the bioinformatics analysis. M.B., R.G. and C.U. performed crystallography study. A.G., A.S., F.R. and J.S. wrote the manuscript. All the authors read and approved the manuscript.

Additional information

Accession codes: Coordinates and structure factors for PA mutant T576E/S559L have been deposited in the RCSB Protein Data Bank under accession codes 5fr3.

Supplementary Information accompanies this paper at http://www.nature.com/naturecommunications

Competing financial interests: A.S., A.G., F.D.S., J.V.D., F.R. and J.S. are mentioned as inventors on a patent filed by the host institute VIB entitled ‘Means and methods for generating improved proteins’. The authors declare no other financial interests in this work.

Reprints and permission information is available online at http://npg.nature.com/reprintsandpermissions/

How to cite this article: Ganesan, A. et al. Structural hot spots for the solubility of globular proteins. Nat. Commun. 7:10816 doi: 10.1038/ncomms10816 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/